Limelight Networks Announces Breakthrough in Interactive Realtime Video Streaming
Limelight Networks, Inc. (Nasdaq: LLNW), a leading provider of edge cloud services, today introduced Limelight Realtime Streaming, the industry’s first globally scalable, sub-second live video streaming solution that’s natively supported by major browsers and devices. The new service also supports integrated realtime data, making it possible to create interactive live online experiences.
As viewing data from the recent FIFA World Cup and live streaming services from social media platforms reveal, people are watching more live events online than ever before. However, streams of live events are typically delayed from the broadcast feed by 30 seconds or more. This often results in poor viewing experiences, loss of reputation when viewers publicly express displeasure, and ultimate loss of revenue.
Limelight Realtime Streaming eliminates these challenges by enabling organizations to stream live video from anywhere in the world to anywhere in the world in less than a second, providing online viewers with the same experience enjoyed by broadcast viewers. The solution leverages the industry-standard WebRTC video format and Limelight’s global edge network to deliver scalable, broadcast-quality, realtime video streaming that can be viewed in all major web browsers without the need for special software or plug-ins.
“With Limelight’s new service, we can provide reliable, high-quality, realtime video streaming to viewers anywhere in the world. The ability to stream video with sub-second latency lets our customers enjoy the action as it happens, wherever they are, on enabled devices or platforms,” said Lukas Seiler, Managing Director Audiovisual at SportRadar, a leading global provider of sports data intelligence.
In addition to eliminating streaming latency, Limelight Realtime Streaming expands the business opportunities associated with existing and new live video applications in areas such as:
- Live sports and events. By making live viewing a more interactive social experience, broadcasters now have additional opportunities to monetize their live video content by offering value-added experiences that are not possible with traditional broadcast.
- Online Gambling. By providing additional opportunities for in-game wagers and reducing opportunities for fraudulent activity, live gaming operators are able to boost productivity and revenues.
- Online Gaming. Realtime video streaming and interactive data functionality enable more immersive gaming experiences, and provide a platform for greater interaction with competitive, live events.
- Health and social care. Realtime video with embedded data enables timely interactions between professionals in time-critical situations, allowing them to share updates and visual information across teams without relying on proprietary equipment, systems and formats.
- Many additional areas where milliseconds matter in video streaming applications such as transportation, emergency and security applications.
“By combining the lowest latency realtime video streaming and data, Limelight is making online viewing experiences more interactive. Limelight’s R&D team has solved the complex problem of delivering sub-second latency live video and data, globally, at scale,” said Bob Lento, Chief Executive Officer at Limelight Networks. “This integration opens up a world of possibilities for how viewers can interact with each other and with content distributors. Many industries can benefit from this capability, and we expect to see a new generation of immersive, low latency, content-rich applications driven by Limelight Realtime Streaming.”
Limelight will be demonstrating its new Realtime Streaming solution and full video delivery services at IBC 2018 in Hall 5, Stand B.52, including new enhancements to its Multi-Device Media Delivery Live solution that simplify the process of recording live events for use as VOD assets.
Limelight Networks, Inc., (NASDAQ: LLNW), a leading provider of digital content delivery, video, cloud security, and edge computing services, empowers customers to provide exceptional digital experiences. Limelight’s edge services platform includes a unique combination of global private infrastructure, intelligent software, and expert support services that enable current and future workflows. For more information, visit www.limelight.com, follow us on Twitter, Facebook, and LinkedIn.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Source Photonics Announces a Comprehensive Portfolio of 50Gb/s Optical Transceivers for 5G Mid-Haul Applications23.9.2019 02:48:00 EEST | Press release
Source Photonics, a market leader of optical transceivers for wireless applications, announces a comprehensive portfolio of 50Gb/s products serving 5G mid-haul applications. Source Photonics’ product portfolio leverages 30 years of high-speed optical transceiver development and high-volume shipments into wireless, datacenter and routing applications, resulting in a broad portfolio of optical transceivers supporting data rates ranging from 125Mb/s to 400Gb/s and transmitting between 300m and 40 km. Source Photonics has leveraged early investments in signal integrity, firmware development, and uncooled high speed DML packaging to release the industry’s most broad 50G product portfolio. 50Gb/s, selected as the mid-haul data rate, provides mid-haul bandwidth requirements not supported by 25Gb/s while also offering meaningful economic advantages over traditional 100Gb/s transceivers. Furthermore, 50Gb/s data rate products support bi-directional applications, where fiber availability is scar
Celltrion Healthcare Receives CHMP Positive Opinion for Novel Subcutaneous Formulation of CT-P13 (biosimilar infliximab) for the Treatment of People With Rheumatoid Arthritis23.9.2019 02:01:00 EEST | Press release
Celltrion Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for CT-P13 SC for marketing authorisation in the European Union (EU) in people with rheumatoid arthritis (RA). CT-P13 SC is the subcutaneous version of Remsima® (biosimilar infliximab, CT-P13). This recommendation will now be reviewed by the European Commission, which has the authority to approve medicines in the EU. A subcutaneous formulation has the potential to enhance treatment options for the use of biosimilar infliximab by providing high consistency in drug exposure and a convenient method of administration.1,2 “Today’s positive CHMP opinion brings us one step closer to providing a personalised treatment approach for people living with rheumatoid arthritis. This marks an important milestone for our business providing people with a new route of administration, and a novel formulation of infliximab,” said Hyoung-Ki
Source Photonics Demonstrates a Full 400G Product Portfolio at ECOC 201923.9.2019 02:01:00 EEST | Press release
Source Photonics, a leading vendor of optical connectivity products for Access and Datacom applications, will demonstrate its complete 400G portfolio with industry partners at ECOC 2019 from September 23-25. Source Photonics has added a wide range of new products to its industry leading portfolio of single-mode products for datacenter and routing applications. The new products leverage the company’s multi-year investment in 28Gbaud and 53Gbaud PAM4 technology and support 400G applications for reaches from 500m up to 40km in small form factor transceivers. Source Photonics’ portfolio of Datacenter and Routing products includes: 400G-DR4 supporting 400GE links over 500m as well as an enhanced reach of up to 2 km (4x100G-FR) with support for breakout into 100G-DR/FR 400G-LR8 supporting 400GE links up to 10 km 400G-ER8 supporting 400GE links up to 40km as technology demonstration “Successful interoperability between optical transceivers and hosts is crucial to rolling out the next higher d
Ipsen to Present New Data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019)20.9.2019 19:30:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today presents results from the matching-adjusted indirect comparison (MAIC) of cabozantinib (Cabometyx®) versus regorafenib (Stivarga®) for the second-line treatment (2L) of patients with advanced hepatocellular carcinoma (aHCC) who received sorafenib as the only prior systemic therapy. Using data from the Phase III CELESTIAL and RESORCE trials, the MAIC showed that cabozantinib offers greater efficacy versus regorafenib. Using data from the Phase III CELESTIAL and RESORCE trials, the MAIC showed that in the 2L CELESTIAL sub-population who had received sorafenib as the only prior systemic therapy, cabozantinib significantly improved progression-free survival (PFS), with an additional 2.4 months provided vs. regorafenib (5.6 months vs. 3.2 months [95% confidence interval (CI): 4.90-7.26], p<0.05). Median overall survival (OS) was also favorable with cabozantinib (11.4 months vs. 10.8 months), though statistical significance was not met
RoboSense RS-LiDAR-M1 Smart LiDAR Sensor Wins AutoSens Awards 201920.9.2019 16:30:00 EEST | Press release
On September 18, 2019, RoboSense announced at Brussels, Belgium that its flagship product RS-LiDAR-M1 Smart LiDAR Sensor has been awarded the elite AutoSens Awards trophy in the “Best Automotive Safety System” category, given to only the highest-rated innovative product or technology in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190920005309/en/ Robosense Along With Other Winnners At The Autosens Awards Ceremony At Brussels, Belgium (Photo: Business Wire) True autonomous driving requires human-like advanced sensing of the environment for driving with little or no human input. The safety of passengers and passers-by is always the priority concern for autonomous driving. When the RS-LiDAR-M1 is integrated into the current autonomous driving car perception system, it overcomes the weaknesses of millimeter wave radar and camera technologies on identifying obstacles, and eliminates car accidents, such
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases20.9.2019 15:00:00 EEST | Press release
Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelheim’s compounds from its retinal disease pipeline portfolio, Boehringer Ingelheim aims to develop novel therapies for retinal diseases. In 2019 there were an estimated 82 million patients in the seven key countries (U.S., Japan, Germany, U.K., Spain, Italy, France) affected by one of the three major forms of retinal disease: Age related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edema (DME). Globally, the prevalence rates of these and other retinal diseases are expected to increase over the next 10 years primarily due to aging populations and the global diabetes epidemic. Despite therapeutic advances in some disease areas during the past
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom